Maxcyte, Inc. · Brief

Next report

10 days

Nov 11 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 6≥ implied

Mar 11 '25—▼−8.36%—

May 7 '25±44.9%▼−11.31%×0.25

Aug 6 '25±37.5%▼−29.90%×0.80

Q3 FY25±64.6%▼−4.43%×0.07

Jan 12 '26±65.8%▼−3.68%×0.06

Q1 FY26—▼−6.81%—

May 12 '26±90.0%▲+24.06%×0.27

Q2 FY26±81.8%▲+9.45%×0.12

quarterimplied−90%0+90%realized×

Q2 FY26±81.8%▲+9.45%×0.12

May '26±90.0%▲+24.06%×0.27

Q1 FY26—▼−6.81%—

Jan '26±65.8%▼−3.68%×0.06

Q3 FY25±64.6%▼−4.43%×0.07

Aug '25±37.5%▼−29.90%×0.80

2 older reports

May '25±44.9%▼−11.31%×0.25

Mar '25—▼−8.36%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 11 report · est.

Bull2

5partners in the disclosed supplier and customer ties in SEC filingsSEC filings

122managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

6 of 6recent reports where the move came in under the options-implied rangeEarnings history

4 of 24largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

MXCT report session

No linked exposure.

Oct 28impliedImplied move: ±72.1% into Nov 11 earnings (Oct 28 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.